Please use this identifier to cite or link to this item: https://hdl.handle.net/2440/68553
Citations
Scopus Web of Science® Altmetric
?
?
Full metadata record
DC FieldValueLanguage
dc.contributor.authorHale, K.-
dc.contributor.authorManaviazar, S.-
dc.contributor.authorGeorge, J.-
dc.date.issued2010-
dc.identifier.citationChemical Communications, 2010; 46(23):4021-4042-
dc.identifier.issn1359-7345-
dc.identifier.issn1364-548X-
dc.identifier.urihttp://hdl.handle.net/2440/68553-
dc.description.abstractHerein we describe our asymmetric total syntheses of (+)-A83586C, (+)-kettapeptin and (+)-azinothricin. We also demonstrate that molecules of this class powerfully inhibit β-catenin/TCF4- and E2F-mediated gene transcription within malignant human colon cancer cells at low drug concentrations.-
dc.description.statementofresponsibilityKarl J. Hale, Soraya Manaviazar and Jonathan George-
dc.language.isoen-
dc.publisherRoyal Soc Chemistry-
dc.rightsThis journal is copyright The Royal Society of Chemistry 2010-
dc.source.urihttp://dx.doi.org/10.1039/c000603c-
dc.subjectCell Line, Tumor-
dc.subjectHumans-
dc.subjectColonic Neoplasms-
dc.subjectDepsipeptides-
dc.subjectPeptides-
dc.subjectTranscription Factors-
dc.subjectTranscription, Genetic-
dc.subjectE2F Transcription Factors-
dc.subjectbeta Catenin-
dc.subjectBasic Helix-Loop-Helix Leucine Zipper Transcription Factors-
dc.subjectTranscription Factor 4-
dc.titleTotal synthesis of (+)-A83586C, (+)- kettapeptin and (+)-azinothricin: powerful new inhibitors of β-catenin/TCF4- and E2F-mediated gene transcription-
dc.title.alternativeTotal synthesis of (+) - A83586C, (+)- kettapeptin and (+)- azinothricin: powerful new inhibitors of beta-catenin/TCF4- and E2F-mediated gene transcription-
dc.typeJournal article-
dc.identifier.doi10.1039/C000603C-
pubs.publication-statusPublished-
dc.identifier.orcidGeorge, J. [0000-0002-7330-2160]-
Appears in Collections:Aurora harvest
Chemistry publications

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.